2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Leukemia, Myeloid, Acute
21
Multiple Myeloma
14
Lymphoma, Non-Hodgkin
14
Congenital Abnormalities
14
Myelodysplastic Syndromes
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Leukemia
11
Lymphoma, Mantle-Cell
9
Hodgkin Disease
9
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma
8
Lymphoma, Follicular
7
Lymphoma, B-Cell, Marginal Zone
7
Leukemia, Myeloid, Accelerated Phase
7
Waldenstrom Macroglobulinemia
6
Graft vs Host Disease
6
Anemia, Refractory, with Excess of Blasts
6
Sezary Syndrome
5
Recurrence
5
Myeloproliferative Disorders
5
Mycosis Fungoides
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Myelomonocytic, Chronic
5
Leukemia, Myeloid, Chronic-Phase
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Hematologic Neoplasms
5
Burkitt Lymphoma
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Interventions
Cyclophosphamide
23
blinatumomab
18
Cytarabine
16
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Daunorubicin
7
Mercaptopurine
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Drug Therapy
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Transplantation
×
Clear all
NCT07443592
2026-03-02
LAL-2025
PETHEMA Foundation
Phase NA
Not yet recruiting
330 enrolled